Jeffrey Busch was appointed as member of the Board of Directors at IMAC Holdings, Inc..
“On September 19, 2024, IMAC Holdings, Inc. (the “Company”) appointed Jeffrey Busch as a member of the Board of Directors of the Company.”
IMAC Holdings, Inc. — fact timeline
Source-grounded facts extracted from IMAC Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cary Sucoff resigned as Director at IMAC Holdings, Inc..
“On September 6, 2024, Cary Sucoff notified the Board of Directors (the “Board”) of IMAC Holdings, Inc. (the “Company”) of his resignation as director, effective on September 9, 2024.”
Matthew Schwartz was appointed as Director at IMAC Holdings, Inc..
“Peter Beitsch, MD, and Matthew Schwartz, MD joined the Board, effective June 26, 2024.”
Peter Beitsch was appointed as Director at IMAC Holdings, Inc..
“Peter Beitsch, MD, and Matthew Schwartz, MD joined the Board, effective June 26, 2024.”
Faith Zaslavsky was appointed as Chief Executive Officer at IMAC Holdings, Inc..
“On May 23, 2024, the Company appointed Faith Zaslavsky as Chief Executive Officer of the Company, effective immediately.”
Jeffrey S. Ervin resigned as Chief Executive Officer at IMAC Holdings, Inc..
“Also on May 23, 2024, Jeffrey S. Ervin notified the Board of his resignation as Chief Executive Officer and director, effective immediately.”
Matthew C. Wallis resigned as Director at IMAC Holdings, Inc..
“On May 23, 2024, Matthew C. Wallis, DC, notified the Board of Directors (the “Board”) of IMAC Holdings, Inc. (the “Company”) of his resignation as director, effective immediately.”
IMAC Holdings, Inc. entered into Securities Purchase Agreement with accredited investors valued at $450,000 (effective 2024-05-13).
“On May 13, 2024, IMAC Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell, and the Investors agreed to purchase, 450 shares of Series F convertible preferred stock, par value $0.001 per share (“Series F Preferred Stock”) and warrants (the “Warrants”, and, together with the Series F Preferred Stock, the “Securities”), for aggregate cash proceeds of $450,000.”
IMAC Holdings, Inc. terminated Agreement and Plan of Merger with Theralink Technologies, Inc. (effective 2024-05-06).
“on May 6, 2024, the Company, IMAC Merger Sub, Inc. (“ Merger Sub ”) and Theralink entered into a Termination Agreement, which immediately terminated the Agreement and Plan of Merger, dated May 26, 2023, by and between the Company, Merger Sub and Theralink”
IMAC Holdings, Inc. entered into Settlement and Release Agreement with Theralink Technologies, Inc. (effective 2024-05-01).
“On May 1, 2024, the Company entered into a Settlement and Release Agreement with Theralink (the “Settlement Agreement”) pursuant to which the parties agreed to a settlement of the default by Theralink under the previously announced Credit Agreement dated April 11, 2024 between the Company as Lender and Theralink as Borrower (the “Theralink Credit Agreement”).”
IMAC Holdings, Inc. entered into Securities Purchase Agreement with various holders (the "Note Holders") of senior secured convertible debentures of Theralink Technologies, Inc. valued at aggregate principal amount outstanding of $16,221,873.89 (effective 2024-04-30).
“On April 30, 2024, IMAC Holdings, Inc. (the “Company”) entered into securities purchase agreements (each, a “Securities Purchase Agreement”) with various holders (the “Note Holders”) of senior secured convertible debentures (the “Notes”) of Theralink Technologies, Inc. (“Theralink”) for the sale of shares of the Company’s newly created Series D Convertible Preferred Stock, $0.001 par value (the “Series D Preferred Stock”).”
IMAC Holdings, Inc. entered into Securities Purchase Agreement with accredited investors valued at aggregate cash proceeds ... of $900,000 (effective 2024-04-10).
“the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell, and the Investors agreed to purchase, 1,276 shares of Series C-2 convertible preferred stock”
IMAC Holdings, Inc. engaged Salberg & Company, P.A. as its auditor.
“On February 8, 2024, the Committee approved the appointment of Salberg & Company, P.A. ("Salberg") as the Company's independent registered public accounting firm”
Cherry Bekaert LLP resigned as auditor of IMAC Holdings, Inc..
“On December 28, 2023, Cherry Bekaert LLP (“Cherry Bekaert”) resigned as the independent registered public accounting firm of IMAC Holdings, Inc. (the “Company”).”
IMAC Holdings, Inc. amended the letter agreement with the Investors valued at $250,000 (effective 2023-12-20).
“On December 20, 2023, the Company entered into a letter agreement with the Investors providing for the sale of an additional aggregate $250,000 of convertible preferred stock (the "Private Placement").”
IMAC Holdings, Inc. entered into the "Private Placement" with several institutional and accredited investors valued at $250,000 (effective 2023-12-20).
“On December 20, 2023, the Company entered into a letter agreement with the Investors providing for the sale of an additional aggregate $250,000 of convertible preferred stock (the "Private Placement").”
Matthew C. Wallis resigned as President at IMAC Holdings, Inc..
“On November 24, 2023, Matthew C. Wallis, DC notified the Company of his resignation as the Company’s President, effective as of that date.”
IMAC Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“will rule in favor of the Company or that the Company will be able to regain compliance with the Equity Rule or maintain compliance with any other Nasdaq requirement in the future. The Company, by filing this Form 8-K, discloses its receipt of the Letter from Nasdaq in accordance with Listing Rule 5810(b).”
IMAC Holdings, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii), 5550(a)(2)).
“September 22, 2023, The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that the Company’s bid price deficiency had been cured and that the Company is in compliance with all applicable listing standards. As previously disclosed, on September 6, 2023, the Company received a letter from Nasdaq notifying the Company that, because the bid price of the Company’s voting common stock and warrants had closed at $0.10 or less for the preceding ten consecutive trading days, in contravention of Nasdaq Listing Rule 5810(c)(3)(A)(iii), the Company’s securities were subject to delisting unless the C”
IMAC Holdings, Inc.: Amendment to Certificate of Incorporation to effect a 1-for-30 reverse stock split (effective 2023-09-07).
“the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation (the “ Amendment ”) to effectuate a reverse stock split of the Company’s Common Stock, affecting the issued and outstanding number of such shares by a ratio of one-for-thirty (the “ Reverse Stock Split ”). The Company filed the Amendment to its Certificate of Incorporation with the State of Delaware effectuating the Reverse Stock Split on September 6, 2023. The Reverse Stock Split became effective in the State of Delaware at 11:59 P.M. ET on Thursday, September 7, 2023.”
IMAC Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(iii)).
“September 6, 2023, the Company received a written notice from Nasdaq’s Listing Qualifications Department (the “ September 2023 Notice ”) notifying that, because the bid price for the Company’s voting common stock, par value $0.001 per share (the “ Common Stock ”) and warrants (the “ Warrants ”), had closed at $0.10 or less for the preceding ten consecutive trading days, in contravention of Nasdaq Listing Rule 5810(c)(3)(A)(iii), the Company’s securities were subject to delisting unless the Company requested a hearing before the Nasdaq Hearings Panel (the “ Panel ”) no later than September 13”
IMAC Holdings, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).
“August 3, 2023, the Company submitted a plan to Nasdaq to grant the Company an extension of time until November 27, 2023 to provide evidence of compliance with the Minimum Equity Rule, and by filing this Current Report on Form 8-K, which includes (1) disclosure of Nasdaq’s deficiency letter and the specific deficiency or deficiencies cited; (2) a description of the completed transaction or event that enabled the Company to satisfy the stockholders’ equity requirement for continued listing; (3) an affirmative statement that, as of the date of the report, the Company believes it has regained com”
IMAC Holdings, Inc.: Filed Certificates of Designation establishing Series A-1 and Series A-2 Convertible Preferred Stock (effective 2023-07-27).
“On July 27, 2023, the Company filed Certificates of Designation of Preferences, Rights and Limitations establishing two series of preferred stock designated as the Series A-1 Convertible Preferred Stock and the Series A-2 Convertible Preferred Stock with the Secretary of State of the State of Delaware.”
IMAC Holdings, Inc. entered into Registration Rights Agreement (effective 2023-07-25).
“The Company also entered into a Registration Rights Agreement, pursuant to which it agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") covering the resale of the shares of the Company’s common stock underlying the Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Warrants no later than 45 days following the closing of the planned merger.”
IMAC Holdings, Inc. entered into Securities Purchase Agreement with several institutional and accredited investors, including existing significant investors of Theralink Technologies, Inc., its previously announced merger partner ("Theralink"), and Theralink’s Chairman valued at aggregate gross proceeds of $4,300,000 (effective 2023-07-25).
“On July 25, 2023, the Company entered into a definitive Securities Purchase Agreement with several institutional and accredited investors, including existing significant investors of Theralink Technologies, Inc., its previously announced merger partner ("Theralink"), and Theralink’s Chairman, for the sale of its convertible preferred stock and warrants (the "Private Placement").”
IMAC Holdings, Inc. shareholders approved The approval (on an advisory, non-binding basis) of the compensation of the Company’s named executive officers. at the 2023-07-05 meeting.
“The approval (on an advisory, non-binding basis) of the compensation of the Company’s named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTE 6,204,204 898,052 133,964 11,235,460”
IMAC Holdings, Inc. shareholders approved The ratification of the appointment of Cherry Bekaert LLP as the Company’s independent registered certified public accounting firm for the fiscal year ending December 31, 2023. at the 2023-07-05 meeting.
“The ratification of the appointment of Cherry Bekaert LLP as the Company’s independent registered certified public accounting firm for the fiscal year ending December 31, 2023. FOR AGAINST ABSTAIN BROKER NON-VOTE 17,417,309 892,354 162,017 0”
IMAC Holdings, Inc. shareholders approved The amendment to the Company’s certificate of incorporation to effect a reverse stock split at a ratio not less than 1-for-15 and not greater than 1-for-30, with the exact ratio to be set within that range at the discretion of the Company’s Board of Directors without further approval or authorizatio at the 2023-07-05 meeting.
“The amendment to the Company’s certificate of incorporation to effect a reverse stock split at a ratio not less than 1-for-15 and not greater than 1-for-30, with the exact ratio to be set within that range at the discretion of the Company’s Board of Directors without further approval or authorization of stockholders. FOR AGAINST ABSTAIN BROKER NON-VOTE 17,256,233 1,016,442 199,013 2”
IMAC Holdings, Inc. shareholders approved Election of five directors nominated by the Board and named in the Proxy Statement at the 2023-07-05 meeting.
“The election of five directors nominated by the Board and named in the Proxy Statement. FOR AGAINST ABSTAIN BROKER NON-VOTE Jeffrey S. Ervin 6,603,325 0 632,895 11,235,460 Matthew C. Wallis 6,652,478 0 583,742 11,235,460 Maurice E. Evans 6,559,972 0 676,248 11,235,460 Michael D. Pruitt 6,529,623 0 706,597 11,235,460 Cary W. Sucoff 6,520,228 0 715,992 11,235,460 The five nominees listed above were elected to the Board.”
IMAC Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 31, 2023, the Company received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1) because the Company’s stockholders’ equity of $996,955, as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the required minimum of $2.5 million, and because, as of May 30, 2023, the Company did not meet the alternative c”
IMAC Holdings, Inc. entered into Agreement and Plan of Merger with Theralink Technologies, Inc. (effective 2023-05-23).
“On May 23, 2023, IMAC Holdings, Inc., a Delaware corporation (Nasdaq: BACK) (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Theralink Technologies, Inc. (OTC: THER), a Nevada corporation (“Theralink”), and IMAC Merger Sub, Inc., a Delaware corporation and a newly formed, wholly owned subsidiary of the Company (“Merger Sub”).”
IMAC Holdings, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“March 23, 2023, the Company received a letter from Nasdaq granting the Company’s request for a 180-day extension to regain compliance with the Minimum Bid Price Requirement (the “Extension Notice”). If at any time prior to September 18, 2023, the closing bid price of the Company’s common stock is at or above $1.00 for a minimum of 10 consecutive business days, Nasdaq will notify the Company that it is in compliance with the Minimum Bid Price Requirement and the matter will be closed. If compliance with the Minimum Bid Price Requirement cannot be demonstrated by September 18, 2023, Nasdaq will”
Ben Lerner resigned as Chief Operating Officer at IMAC Holdings, Inc..
“On February 28, 2023, Dr. Ben Lerner notified the Company of his resignation as the Company’s Chief Operating Officer to pursue other interests, effective as of February 28, 2023.”
Dr. Matthew C. Wallis resigned as Chief Operating Officer at IMAC Holdings, Inc..
“President Dr. Matthew C. Wallis (who resigned the title of Chief Operating Officer to bring in Dr. Lerner)”
Dr. Ben Lerner was appointed as Chief Operating Officer at IMAC Holdings, Inc..
“Effective February 21, 2022, Dr. Ben Lerner was appointed to be our Chief Operating Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.